Find the right fit for you - faster
Get tailored insights about working at Theravance in one quick step.
Theravance Snapshot
Theravance figures there's no sense in re-inventing the wheel. The biotechnology firm takes aim at already proven biological targets, taking advantage of previous years of research to create more effective, next-generation treatments. Its development programs focus on respiratory disease, bacterial infections, and gastrointestinal and neurological conditions. Its sole marketed product, VIBATIV (an injectable antibiotic approved to treat skin infections and hospital-acquired pneumonia) was successfully developed and commercialized with partner Astellas. In an exclusive alliance with GlaxoSmithKline (GSK), Theravance is developing a next-generation replacement for GSK's asthma medication Advair.
